These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

652 related articles for article (PubMed ID: 3319120)

  • 1. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
    Libman I; Gawel MJ; Riopelle RJ; Bouchard S
    Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bromocriptine in the treatment of Parkinson's disease: a double-blind study against L-dopa/carbidopa.
    Gawel M; Riopelle R; Libman I; Bouchard S
    Adv Neurol; 1987; 45():535-8. PubMed ID: 3548263
    [No Abstract]   [Full Text] [Related]  

  • 3. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.
    Hutton JT; Morris JL; Bush DF; Smith ME; Liss CL; Reines S
    Neurology; 1989 Nov; 39(11 Suppl 2):67-72; discussion 72-3. PubMed ID: 2685652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
    Olanow CW; Hauser RA; Gauger L; Malapira T; Koller W; Hubble J; Bushenbark K; Lilienfeld D; Esterlitz J
    Ann Neurol; 1995 Nov; 38(5):771-7. PubMed ID: 7486869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.
    Hauser RA; Koller WC; Hubble JP; Malapira T; Busenbark K; Olanow CW
    Mov Disord; 2000 May; 15(3):485-9. PubMed ID: 10830413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind study of bromocriptine and L-dopa in de novo Parkinson's disease. Short-term results.
    Riopelle RJ; Gawel MJ; Libman I; King DB; McLean DR; Paulseth R; Raphy B; Bouchard S
    Eur Neurol; 1988; 28 Suppl 1():11-4. PubMed ID: 3288477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dosage treatment in de novo patients with Parkinson's disease: a prospective study.
    van der Drift JH
    Adv Neurol; 1987; 45():529-34. PubMed ID: 3825731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Sydney multicentre study of Parkinson's disease. The first 18 months.
    Hely MA; Morris JG; Rail D; O'Sullivan DJ; Williamson PM; Genge S; Reid WG; Broe GA
    Med J Aust; 1987 Feb; 146(4):195-8. PubMed ID: 3553878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapy: problems and practices.
    Muenter MD
    Clin Neuropharmacol; 1986; 9 Suppl 1():S23-36. PubMed ID: 3708606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
    Brannan T; Yahr MD
    Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of Parkinson's disease with the combination drug L-carbidopa/L-dopa. Report on a 2 years study].
    Hayek J
    Schweiz Med Wochenschr; 1977 Apr; 107(14):474-9. PubMed ID: 847450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease.
    Olanow CW; Alberts MJ
    Adv Neurol; 1987; 45():555-60. PubMed ID: 3548266
    [No Abstract]   [Full Text] [Related]  

  • 14. Superior clinical efficacy of Sinement CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open and a double-blind, double-dummy, multicenter treatment evaluation. Dutch Sinement CR Study Group.
    Wolters EC; Horstink MW; Roos RA; Jansen EN
    Adv Neurol; 1993; 60():648-52. PubMed ID: 8420204
    [No Abstract]   [Full Text] [Related]  

  • 15. Risk factors for motor response complications in L-dopa-treated parkinsonian patients.
    Peppe A; Dambrosia JM; Chase TN
    Adv Neurol; 1993; 60():698-702. PubMed ID: 8420213
    [No Abstract]   [Full Text] [Related]  

  • 16. [Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study].
    Chaná P; Fierro A; Reyes-Parada M; Sáez-Briones P
    Rev Med Chil; 2003 Jun; 131(6):623-31. PubMed ID: 12942590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sinemet CR in Parkinson's disease.
    Pfeiffer RF; Wilken KE; Glaeske CS; Hofman R
    Nebr Med J; 1991 Jan; 76(1):8-10. PubMed ID: 1997878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM; Hoey M; Kutt H; McDowell FH
    Clin Neuropharmacol; 1988 Apr; 11(2):168-73. PubMed ID: 3378225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bromocriptine in Parkinsonian syndromes. Results obtained in a group of patients treated for 8 months].
    Quattrini A; Paggi A; Del Pesce M; Di Bella P
    Riv Patol Nerv Ment; 1978; 99(3):150-63. PubMed ID: 752907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.